# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and gl...
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $24 to...
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...